Cancer Hetergeneity Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Why is exome sequencing cheaper than whole genome sequencing?

A

Exomes make up the coding regions of DNA and only make up 1% of the genome
-therefore exome sequencing is cheaper and more manageable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are some distinct properties that cancer cells show?

A
Morphology
Metabolism
Proliferation
Metastatic potential
Gene expression
Genetic alterations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is inter-patient heterogeneity?

A

A subdivision of dividing cancer by histology, the driver of mutation and origin
-each patient has a unique cancer because of its genetic and genomic features

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does inter-patient heterogeneity have consequences on and why?

A

Treatment

Only a subset of individuals bear alterations compatible with response to a drug treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are trunk and branch mutations?

A

Trunk mutations are ubiquitous, and present in the initial tumour

Branch mutations are regional and represent secondary and local mutations. Different mutations can affect the same gene (convergent evolution)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Explain the branching evolution of a cancer

A

Trunk contains all of the original initiator events
Internal branches are the first clones to initiate heterogeneity
Terminal branches are current active clones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are clones?

A

A homogenous group of cells sharing the same ancestor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which type of mutation has a cancer cell fraction of 100% within a tumour?

A

Trunk/founder mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What does it mean if a mutation has a cancer cell fraction of anything less than one?

A

The tumour cells with these mutations are sub-clones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What shales heterogeneity?

A

The fittest clone survives, where therapy is the selective pressure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the therapeutic implications of heterogeneity?

A

Get resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Give an example of where resistance can be seen due to tumour heterogeneity

A

Panitumumab and cetuximab inhibit Ras, inhibiting growth of CRC
Resistance occurs due to acquisition of KRas mutations (however the mutations may have already existed)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Give an example of how resistance can occur in melanoma

A

Vemurafenib inhibits BRAF

Get further mutations to BRAF leading to MAPK deactivation via N-Ras and over-eps region of tyrosine kinase receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Give features of driver mutations

A

Implicated in omcogenesis
Confer a growth advantage in the cancer cell
Positively selected
May not be required for maintenance of the final cancer though often is

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Give features of passenger mutations

A

Do not contribute to cancer development
Found within cancer genomes because somatic mutations without functional consequences often occur during cell division but are not selected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Give features of deleterious mutations

A

Impair cell survival

Subject to negative selections so are absent in the cancer genome

17
Q

Why is regional variation in branch mutations sometimes important?

A

A branch mutation can be a driver gene so not found in all areas of the tumour
This can affect treatment depending on where the biopsy is taken from

18
Q

Give an example of when a branch mutation is also a driver mutation

A

Lung cancer

  • BRAF is activated in the trunk
  • PIK3CA mutation only in R3
  • so a biopsy in R3 suggests treatment inhibiting PIK3 signalling
  • a biopsy elsewhere indicates BRAF inhibitors
  • therefore, R3 would likely resist this treatment
19
Q

What allows us to understand tumour heterogeneity?

A

DNA sequencing technologies eg illumine instruments, which uses sequencing by synthesis technology